Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Cisplatin and Radiation for Resected Stage II/III NSCLC
NCT00530634Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Aug 1999
- Primary completion
- Jun 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Primary endpoint: Progression-free Survival at 2 years. Started Aug 1999; status: terminated.
02
Drugs
gemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00530634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530634.